Physician profile
Mark Kocab
NPI 1942271606
$4,576.95
in general payments reported to CMS, 2019-2025
27 companies · $87.52 in 2025
The $87.52 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $349 · 2021: $757 · 2022: $1,007 · 2023: $854 · 2024: $765 · 2025: $87.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.35 | 2019-2025 | |
| Celgene Corporation | $359.23 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $282.34 | 2020-2024 | Stelara, Remicade, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $226.06 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $225.73 | 2019-2024 | Endoarmor, Axios |
| Pfizer INC. | $156.87 | 2019-2024 | |
| Qol Medical, LLC | $136.56 | 2023-2024 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.90 | 2019-2023 | Trulance, Xifaxan |
| Genzyme Corporation | $88.22 | 2024 | |
| Nestle Healthcare Nutrition INC. | $87.94 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $78.00 | 2024 | |
| Ironwood Pharmaceuticals, INC | $68.36 | 2019-2024 | |
| Allergan, INC. | $65.57 | 2019 | |
| Gilead Sciences, INC. | $64.84 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $63.93 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $56.86 | 2024 | Voquezna |
| Mauna Kea Technologies, INC. | $48.15 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $42.18 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $31.43 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $21.65 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $20.93 | 2023 | Andexxa |
| Teleflex LLC | $17.47 | 2024 | Solesta |
| Shionogi INC | $16.72 | 2019 | |
| Ucb, INC. | $16.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Shire North American Group INC | $16.00 | 2019 | |
| Redhill Biopharma INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kocab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.